Lattanzi, Simona http://orcid.org/0000-0001-8748-0083
Cagnetti, Claudia
Foschi, Nicoletta
Ciuffini, Roberta
Osanni, Elisa
Chiesa, Valentina
Dainese, Filippo
Dono, Fedele
Canevini, Maria Paola
Evangelista, Giacomo
Paladin, Francesco
Bartolini, Emanuele
Ranzato, Federica
Nilo, Annacarmen
Pauletto, Giada
Marino, Daniela
Rosati, Eleonora
Bonanni, Paolo
Marrelli, Alfonso
Funding for this research was provided by:
Università Politecnica delle Marche
Article History
Accepted: 16 May 2021
First Online: 2 June 2021
Declarations
:
: Open access funding provided by Università Politecnica delle Marche within the CRUI-CARE Agreement. No funding has been received for the conduct of this study.
: Simona Lattanzi has received speaker's or consultancy fees from Eisai, GW Pharmaceuticals, and UCB Pharma and has served on advisory boards for Angelini, Arvelle Therapeutics, BIAL, and GW Pharmaceuticals. Valentina Chiesa has received speaker's or consultancy fees from Eisai, UCB Pharma, and Livanova. Fedele Dono has received speaker's fees from Eisai. Maria Paola Canevini has received speaker’s or consultancy fees from Bial, EISAI, Italfarmaco, Sanofi, and UCB. All other authors have nothing to disclose.
: The study was approved by the ethical committee at any participating center and conducted in accordance with the Declaration of Helsinki.
: Informed consent was obtained from every patient or legal representative.
: Not applicable.
: Anonymized data will be shared by request from any qualified investigator.
: Not applicable.
: SL drafted the concept, analyzed data and wrote the manuscript. CC, NF, CR, EO, VC, FD, FD, MPC, GE, FP, EB, FR, AN, GP, DM, ER, PB, and AM collected data. All authors critically revised the work and contributed to the final manuscript. All authors approved the final manuscript for submission.